• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变DNA修复基因在膀胱癌中的作用及意义的分子与临床见解

Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.

作者信息

Abbosh Philip H, Plimack Elizabeth R

机构信息

Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.

Department of Urology, Einstein Medical Center, Philadelphia, PA, USA.

出版信息

Bladder Cancer. 2018 Jan 20;4(1):9-18. doi: 10.3233/BLC-170129.

DOI:10.3233/BLC-170129
PMID:29430503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5798524/
Abstract

DNA damage response and repair genes (DDR genes) are commonly mutated in bladder cancer. The biological impact of these mutations is an area of intense basic, translational, and clinical interest. As next generation sequencing increases its foothold in the treatment of localized and advanced bladder cancer, the role of DDR genes will continue to evolve. We review the inventory and biology of DDR genes in bladder cancer and describe known and candidate roles for loss of DDR genes to engender therapeutic susceptibilities to various anti-cancer agents.

摘要

DNA损伤反应与修复基因(DDR基因)在膀胱癌中普遍发生突变。这些突变的生物学影响是基础、转化和临床研究的热点领域。随着下一代测序技术在局部和晚期膀胱癌治疗中的应用不断增加,DDR基因的作用将持续演变。我们综述了膀胱癌中DDR基因的概况和生物学特性,并描述了DDR基因缺失在导致对各种抗癌药物产生治疗敏感性方面已知的和潜在的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/780d2f63210b/blc-4-blc170129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/355935d3a553/blc-4-blc170129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/9b4669016c15/blc-4-blc170129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/780d2f63210b/blc-4-blc170129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/355935d3a553/blc-4-blc170129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/9b4669016c15/blc-4-blc170129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b89/5798524/780d2f63210b/blc-4-blc170129-g003.jpg

相似文献

1
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.突变DNA修复基因在膀胱癌中的作用及意义的分子与临床见解
Bladder Cancer. 2018 Jan 20;4(1):9-18. doi: 10.3233/BLC-170129.
2
Urothelial carcinoma of the bladder and the upper tract: disparate twins.膀胱和上尿路尿路上皮癌:迥异的双生子。
J Urol. 2013 Apr;189(4):1214-21. doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.
3
Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?膀胱和上尿路尿路上皮癌的分子特征的前瞻性比较——是否有生物学不一致的证据?
J Urol. 2014 Apr;191(4):926-31. doi: 10.1016/j.juro.2013.09.031. Epub 2013 Sep 20.
4
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.欧洲癌症研究与治疗组织晚期尿路上皮癌研究中原发肿瘤位置对生存的影响。
J Urol. 2018 May;199(5):1149-1157. doi: 10.1016/j.juro.2017.11.068. Epub 2017 Nov 20.
5
Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.人类错配修复基因hMSH2的表达:一种尿路上皮恶性肿瘤的潜在标志物。
Cancer. 2000 May 15;88(10):2333-41.
6
Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison.上尿路和膀胱尿路上皮癌的分子分析:微阵列比较结果
PLoS One. 2015 Aug 28;10(8):e0137141. doi: 10.1371/journal.pone.0137141. eCollection 2015.
7
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.DNA修复基因缺陷可预测肌层浸润性膀胱癌对基于顺铂的新辅助化疗的反应。
Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.
8
Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.浸润性尿路上皮癌的辅助化疗:甲氨蝶呤、长春新碱、顺铂、环磷酰胺、阿霉素和博来霉素(MVP-CAB)方案的经验:初步报告
Jpn J Clin Oncol. 1993 Oct;23(5):291-8.
9
FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.FGF7 过表达是上尿路和膀胱尿路上皮癌患者的独立预后指标。
J Urol. 2015 Jul;194(1):223-9. doi: 10.1016/j.juro.2015.01.073. Epub 2015 Jan 23.
10
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.肌层浸润性膀胱癌和上尿路尿路上皮癌的围手术期免疫治疗
Urol Clin North Am. 2018 May;45(2):287-295. doi: 10.1016/j.ucl.2017.12.011.

引用本文的文献

1
PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.PARP抑制剂在泌尿生殖系统癌症中的应用:超越前列腺癌的新范式。
Int J Urol. 2025 Sep;32(9):1091-1101. doi: 10.1111/iju.70100. Epub 2025 Jun 9.
2
Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients.DNA 修复基因的表观遗传失活可作为膀胱癌患者有前途的预后和预测生物标志物。
Mol Genet Genomics. 2022 Nov;297(6):1671-1687. doi: 10.1007/s00438-022-01950-x. Epub 2022 Sep 8.
3
A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.

本文引用的文献

1
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.化疗耐药性肌肉浸润性膀胱癌的突变模式。
Nat Commun. 2017 Dec 19;8(1):2193. doi: 10.1038/s41467-017-02320-7.
2
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
3
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1(PD-1)阻断疗法的反应。
一项将螺内酯重新用于增强膀胱癌化疗反应的临床前研究。
Mol Cancer Ther. 2022 May 4;21(5):786-798. doi: 10.1158/1535-7163.MCT-21-0613.
4
Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.相互排斥的突变谱定义了肌肉浸润性膀胱癌中具有功能相关性的基因。
PLoS One. 2022 Jan 24;17(1):e0259992. doi: 10.1371/journal.pone.0259992. eCollection 2022.
5
Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.根治性膀胱切除术治疗肌层浸润性膀胱癌患者微小残留病灶的尿液肿瘤 DNA 检测:一项队列研究。
PLoS Med. 2021 Aug 31;18(8):e1003732. doi: 10.1371/journal.pmed.1003732. eCollection 2021 Aug.
6
The repair gene - a potential oncogene.修复基因——一种潜在的癌基因。
Oncol Rev. 2021 Jul 2;15(1):519. doi: 10.4081/oncol.2021.519. eCollection 2021 Feb 26.
7
Developing Precision Medicine for Bladder Cancer.开发膀胱癌精准医学。
Hematol Oncol Clin North Am. 2021 Jun;35(3):633-653. doi: 10.1016/j.hoc.2021.02.008. Epub 2021 Apr 10.
8
The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer.在膀胱癌放疗反应的DNA损伤反应生物标志物中,将检测方法与生物学相匹配面临的挑战。
Transl Androl Urol. 2019 Dec;8(Suppl 5):S514-S516. doi: 10.21037/tau.2019.07.05.
9
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.膀胱癌,一种独特的模型,可用于了解癌症免疫并开发免疫疗法。
J Pathol. 2019 Oct;249(2):151-165. doi: 10.1002/path.5306. Epub 2019 Jun 24.
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
4
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
5
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.循环游离 DNA 指导 PARP 抑制治疗前列腺癌。
Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.
6
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.DNA 损伤反应和修复基因改变与铂类治疗的晚期尿路上皮癌患者的生存改善相关。
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.
7
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.纳武利尤单抗单药治疗复发性转移性尿路上皮癌(CheckMate 032):一项多中心、开放标签、两阶段、多臂1/2期试验。
Lancet Oncol. 2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X. Epub 2016 Oct 9.
8
Classification and characterization of microsatellite instability across 18 cancer types.18 种癌症中微卫星不稳定性的分类和特征描述。
Nat Med. 2016 Nov;22(11):1342-1350. doi: 10.1038/nm.4191. Epub 2016 Oct 3.
9
Genomic characterization of response to chemoradiation in urothelial bladder cancer.尿路上皮膀胱癌对放化疗反应的基因组特征分析
Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.
10
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.化疗反应生物标志物ERCC2在肌层浸润性尿路上皮膀胱癌中的临床验证
JAMA Oncol. 2016 Aug 1;2(8):1094-6. doi: 10.1001/jamaoncol.2016.1056.